## ROCHE HOLDINGS AG GENUSSCHEINE NPV

ISIN: CH0012032048 WKN: 1203204 Asset Class: Stock



#### **Company Profile**

Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

|                                | 20             | 23                     | 20             | 22                     | 20             | 21                     |
|--------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| Financial figures              |                | Liabilities and equity |                | Liabilities and equity |                | Liabilities and equity |
| Current assets                 | 33,446,000,000 |                        | 33,816,000,000 |                        | 35,627,000,000 |                        |
| Common stock capital           |                | 107,000,000            |                | 107,000,000            |                | 160,000,000            |
| Fixed assets                   | 57,022,000,000 |                        | 54,335,000,000 |                        | 56,690,000,000 |                        |
| Equity capital of a company    |                | 33,263,000,000         |                | 32,015,000,000         |                | 28,345,000,000         |
| Cash and cash equivalents      | 5,376,000,000  |                        | 4,991,000,000  |                        | 6,850,000,000  |                        |
| Accrued liabilities            |                | 5,438,000,000          |                | 5,672,000,000          |                | 7,545,000,000          |
| Other assets                   | -              |                        | -              |                        | -              |                        |
| Current liabilities            |                | 24,824,000,000         |                | 27,239,000,000         |                | 38,416,000,000         |
| Prepayments and accrued income | -              |                        | -              |                        | -              |                        |
| Non-current liabilities        |                | 32,381,000,000         |                | 28,897,000,000         |                | 25,556,000,000         |
| Different income               |                | -                      |                | -                      |                | -                      |
| Other liabilities              |                | 259,000,000            |                | 298,000,000            |                | 282,000,000            |
| Total assets                   | 90,468,000,000 | 90,468,000,000         | 88,151,000,000 | 88,151,000,000         | 92,317,000,000 | 92,317,000,000         |

#### **Balance notes**

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS    | IFRS    | IFRS    |
| Employees           | 103,605 | 103,613 | 100,920 |
| Equity ratio        | 41.13%  | 40.88%  | 34.88%  |
| Debt-equity ratio   | 143.12% | 144.61% | 186.69% |

### **Others**

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 12.20% | 17.08% | 14.16% |

# **ROCHE HOLDINGS AG GENUSSCHEINE NPV**

ISIN: CH0012032048 WKN: 1203204 Asset Class: Stock

| Income statement   |                |                |                |
|--|----------------|----------------|----------------|
|  | 2023           | 2022           | 2021           |
| Turnover   | 58,716,000,000 | 63,281,000,000 | 62,801,000,000 |
| Net income   | 11,498,000,000 | 12,421,000,000 | 13,930,000,000 |
| EBIT   | 15,593,328,200 | 17,719,548,800 | 18,518,055,800 |
| Operating income before taxes                                | 14,111,000,000 | 16,368,000,000 | 17,400,000,000 |
| Cash Flow  | 15,493,000,000 | 17,890,000,000 | 20,569,000,000 |
| Net interest income  | -828,000,000   | -608,000,000   | -341,000,000   |
| Research and development expenses                            | 13,231,000,000 | 14,050,000,000 | 13,707,000,000 |
| Income taxes   | 1,721,000,000  | 2,796,000,000  | 2,463,000,000  |
| Result from investments in subsidaries, associates and other | -32,000,000    | -41,000,000    | -2,000,000     |
| Revenues per employee  | 591,552        | 637,494        | 649,541        |

| Board of Director  |                                     |
|--------------------|-------------------------------------|
| Doard of Director  | 5                                   |
| Akiko Iwasaki      | Member of the administrative board  |
| Claudia Dyckerhoff | Member of the administrative board  |
| Jemilah Mahmood    | Member of the administrative board  |
| Joerg Duschmale    | Member of the administrative board  |
| Patrick Frost      | Member of the administrative board  |
| Richard Lifton     | Member of the administrative board  |
| Ulf Mark Schneider | Member of the administrative board  |
| André Hoffmann     | Member of the administrative board  |
| Anita Hauser       | Member of the administrative board  |
| Bernard Poussot    | Member of the administrative board  |
| Severin Schwan     | Chairman of the administrative boar |

| Members of Management Board |                               |  |
|-----------------------------|-------------------------------|--|
|                             |                               |  |
| Thomas Schinecker           | Chairman of Managing Board    |  |
| Alan Hippe                  | Member of Executive Committee |  |
| Aviv Regev                  | Member of Executive Committee |  |
| Dr. Hans Clevers            | Member of Executive Committee |  |
| James H. Sabry              | Member of Executive Committee |  |
| Levi Garraway               | Member of Executive Committee |  |
| Barbara Schädler            | Member of Executive Committee |  |
| Claudia Böckstiegel         | Member of Executive Committee |  |
| Cristina A. Wilbur          | Member of Executive Committee |  |
| Matt Sause                  | Member of Executive Committee |  |
| Silke Hörnstein             | Member of Executive Committee |  |
| Teresa Graham               | Member of Executive Committee |  |